Key result
Atenolol reduces anginal attacks versus placebo and matches propranolol efficacy.
RCT (n=14)
Double-blind
Answers are grounded in this paper and cite their sources.
Fourteen patients with angina pectoris completed a double blind trial of atenolol 25 mg, 50 mg, and 100 mg twice daily and propranolol 80 mg thrice daily. In comparison with placebo, all active treatments significantly reduced anginal attacks, consumption of glyceryl trinitrate, resting and exercise heart rate, resting and exercise systolic blood pressure, and significantly prolonged exercise time. There was no significant difference between the effects of propranolol and atenolol. Nine patients completed a further trial comparing atenolol given once or twice daily. Both regimens were effective and there was no significant difference between the reductions in anginal attacks, glyceryl trinitrate consumption, systolic blood pressure, or heart rate. Twenty-four-hour ambulatory electrocardiograms showed that atenolol consistently reduced heart rate throughout the 24-hour period whether given once or twice daily. Atenolol is a potent antianginal agent which, in most patients, is likely to be effective once daily.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (1978) conducted an RCT in Angina pectoris (n=14). Atenolol vs. Propranolol 80 mg thrice daily and placebo was evaluated on Anginal attacks, glyceryl trinitrate consumption, resting and exercise heart rate, resting and exercise systolic blood pressure, and exercise time. Atenolol reduced anginal attacks vs placebo in 14 patients, with no significant difference vs propranolol thrice daily.
Synapse has enriched 10 related papers. Consider them for comparative context: